Pittsburgh

The trials here

What the 24 trials at this site are about, from their registry records.

Conditions

• HIV5 trials
• Asthma4 trials
• Colorectal cancer3 trials
• Lung cancer3 trials
• Ovarian cancer2 trials
• ANCA-associated vasculitis1 trial
• Endometrial cancer1 trial
• Fatty liver disease (MASLD/MASH)1 trial
• Head and neck cancer1 trial
• Irritable bowel syndrome1 trial
• Liver and biliary tract cancer1 trial
• Lupus (SLE)1 trial
• and 3 more

Phase

• Phase 312 trials
• Phase 26 trials
• Phase 12 trials
• Phase 2/32 trials
• Phase 41 trial

Status

• Active, not recruiting13 trials
• Completed6 trials
• Recruiting4 trials
• Withdrawn1 trial

Lead sponsor

• GlaxoSmithKline15 trials
• ViiV Healthcare5 trials
• Tesaro, Inc.4 trials

Running trials

• Recruiting

  A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically Suppressed

  NCT07650916· Phase 3· ViiV Healthcare· Source

  Contact: Chiu-Bin Hsiao (principal investigator)

• Recruiting

  A Study to Investigate Abdominal Symptoms With Camlipixant Compared With Placebo in Adults With Irritable Bowel Syndrome - Diarrhea (IBS-D) and Irritable Bowel Syndrome - Mixed (IBS-M)

  NCT07519395· Phase 2· GlaxoSmithKline· Source

  Contact: Shari Rozen (principal investigator)

• Active, not recruiting

  A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV

  NCT07053384· Phase 1· ViiV Healthcare· Source

• Active, not recruiting

  A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled Asthma

  NCT06748053· Phase 2· GlaxoSmithKline· Source

• Active, not recruiting

  A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)

  NCT06741397· Phase 2· ViiV Healthcare· Source

• Active, not recruiting

  Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma

  NCT06372496· Phase 4· GlaxoSmithKline· Source

• Recruiting

  A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

  NCT06256588· Phase 3· GlaxoSmithKline· Source

  Contact: Larisa Greenberg (principal investigator)

• Recruiting

  A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

  NCT05878717· Phase 2/3· GlaxoSmithKline· Source

  Contact: Robyn Domsic (principal investigator)

• Active, not recruiting

  A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer

  NCT05723562· Phase 2· GlaxoSmithKline· Source

• Active, not recruiting

  Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)

  NCT05263934· Phase 3· GlaxoSmithKline· Source

• Active, not recruiting

  Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

  NCT04915755· Phase 3· GlaxoSmithKline· Source

• Active, not recruiting

  Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy

  NCT04655976· Phase 2/3· GlaxoSmithKline· Source

• Active, not recruiting

  A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer

  NCT03981796· Phase 3· Tesaro, Inc.· Source

• Active, not recruiting

  A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer

  NCT03602859· Phase 3· Tesaro, Inc.· Source

• Active, not recruiting

  Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults

  NCT03299049· Phase 3· ViiV Healthcare· Source

• Active, not recruiting

  Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults

  NCT02951052· Phase 3· ViiV Healthcare· Source

• Active, not recruiting

  A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)

  NCT02817633· Phase 1· Tesaro, Inc.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Head and neck cancer1 recruiting
• HIV1 recruiting
• Irritable bowel syndrome1 recruiting
• Systemic sclerosis (scleroderma)1 recruiting

Closed trials

• Completed

  A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants ≥ 18 Years of Age With Asthma

  NCT06261957· Phase 3· GlaxoSmithKline· Source

• Recruiting

  Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

  NCT05855200· Phase 3· GlaxoSmithKline· Source

• Completed

  Phase 2b Study of GSK4532990 in Adults With NASH

  NCT05583344· Phase 2· GlaxoSmithKline· Source

• Completed

  A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype

  NCT04718389· Phase 3· GlaxoSmithKline· Source

• Completed

  Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-Small Cell Lung Cancer

  NCT04475939· Phase 3· GlaxoSmithKline· Source

• Completed

  A Study of Niraparib Combined With Bevacizumab Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

  NCT03326193· Phase 2· Tesaro, Inc.· Source

• Completed

  Safety and Effectiveness of BENLYSTA (Belimumab) in Systemic Lupus Erythematosus (SLE) Registry

  NCT01729455· GlaxoSmithKline· Source